Background: The tumour microenvironment (TME) consisting of tumour cells and multiple stromal cell types regulate tumour growth, invasion and metastasis. While the concept of TME and presence of stromal cellular components is widely established in cancers, its significance in the paediatric intraocular malignancy, retinoblastoma (RB), remains unknown. Methods: The study qualitatively identified the presence of multiple stromal cellular subtypes in RB TME by immunohistochemistry. Results: Results of the study identified the presence of stromal cell types such as endothelial cells, tumour-associated macrophages, fibroblasts, cancer-associated fibroblasts, retinal astrocytes and glia in RB TME. The extent of stromal marker positivity, however, did not correlate with histopathological features of RB. Conclusions: The findings of the study convincingly suggest the presence of a stromal component in RB tumours. The interactions between stromal cells and tumour cells might be of profound importance in RB progression.

Keywords:
Retinoblastoma, Stromal cells, Tumour microenvironment, Endothelial cells, Fibroblasts, Tumour-associated macrophages
1.
Minoda K: [Genetics of retinoblastoma]. Nihon Rinsho. Jap J Clin Med 1995; 53: 2774–2778.
2.
Lohmann DR: RB1 gene mutations in retinoblastoma. Hum Mutat 1999; 14: 283–288.
3.
Lee WH, Murphree AL, Benedict WF: Expression and amplification of the N-myc gene in primary retinoblastoma. Nature 1984; 309: 458–460.
4.
Dimaras H, Kimani K, Dimba EA, Gronsdahl P, White A, Chan HS, Gallie BL: Retinoblastoma. Lancet 2012; 379: 1436–1446.
5.
Turaka K, Shields CL, Meadows AT, Leahey A: Second malignant neoplasms following chemoreduction with carboplatin, etoposide, and vincristine in 245 patients with intraocular retinoblastoma. Pediatr Blood Cancer 2012; 59: 121–125.
6.
Shields CL, Fulco EM, Arias JD, Alarcon C, Pellegrini M, Rishi P, Kaliki S, Bianciotto CG, Shields JA: Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy. Eye (Lond) 2013; 27: 253–264.
7.
Shields CL, Manjandavida FP, Lally SE, Pieretti G, Arepalli SA, Caywood EH, Jabbour P, Shields JA: Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma. Ophthalmology 2014; 121: 1453–1460.
8.
Francis JH, Brodie SE, Marr B, Zabor EC, Mondesire-Crump I, Abramson DH: Efficacy and toxicity of intravitreous chemotherapy for retinoblastoma: four-year experience. Ophthalmology 2017; 124: 488–495.
9.
Abramson DH: Periocular chemotherapy for retinoblastoma: success with problems? Arch Ophthalmol 2005; 123: 128–129.
10.
Shields CL, Shields JA: Intra-arterial chemotherapy for retinoblastoma: the beginning of a long journey. Clin Exp Ophthalmol 2010; 38: 638–643.
11.
Shields CL, Manjandavida FP, Arepalli S, Kaliki S, Lally SE, Shields JA: Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results. JAMA Ophthalmol 2014; 132: 319–325.
12.
Senthebane DA, Rowe A, Thomford NE, Shipanga H, Munro D, Mazeedi M, Almazyadi HAM, Kallmeyer K, Dandara C, Pepper MS, Parker MI, Dzobo K: The role of tumor microenvironment in chemoresistance: to survive, keep your enemies closer. Int J Mol Sci 2017; 18:pii:E1586.
13.
Banat GA, Tretyn A, Pullamsetti SS, Wilhelm J, Weigert A, Olesch C, Ebel K, Stiewe T, Grimminger F, Seeger W, Fink L, Savai R: Immune and inflammatory cell composition of human lung cancer stroma. PLoS One 2015; 10:e0139073.
14.
Maturu P, Overwijk WW, Hicks J, Ekmekcioglu S, Grimm EA, Huff V: Characterization of the inflammatory microenvironment and identification of potential therapeutic targets in wilms tumors. Transl Oncol 2014; 7: 484–492.
15.
Mao Y, Keller ET, Garfield DH, Shen K, Wang J: Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev 2013; 32: 303–315.
16.
Hamada S, Masamune A, Shimosegawa T: Alteration of pancreatic cancer cell functions by tumor-stromal cell interaction. Front Physiol 2013; 4: 318.
17.
Hashimoto O, Yoshida M, Koma Y, Yanai T, Hasegawa D, Kosaka Y, Nishimura N, Yokozaki H: Collaboration of cancer-associated -fibroblasts and tumour-associated macrophages for neuroblastoma development. J Pathol 2016; 240: 211–223.
18.
Byrd T, Grossman RG, Ahmed N: Medulloblastoma-biology and microenvironment: a review. Pediatr Hematol Oncol 2012; 29: 495–506.
19.
Watnick RS: The role of the tumor microenvironment in regulating angiogenesis. Cold Spring Harb Perspect Med 2012; 2: a006676.
20.
Yuan Y, Jiang YC, Sun CK, Chen QM: Role of the tumor microenvironment in tumor progression and the clinical applications (Review). Oncol Rep 2016; 35: 2499–2515.
21.
Nyberg P, Salo T, Kalluri R: Tumor microenvironment and angiogenesis. Front Biosci 2008; 13: 6537–6553.
22.
Lorusso G, Ruegg C: The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol 2008; 130: 1091–1103.
23.
Quail DF, Joyce JA: Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013; 19: 1423–1437.
24.
Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SG, Hoadley KA, Rashid NU, Williams LA, Eaton SC, Chung AH, Smyla JK, Anderson JM, Kim HJ, Bentrem DJ, -Talamonti MS, Iacobuzio-Donahue CA, Hollingsworth MA, Yeh JJ: Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal -adenocarcinoma. Nature genetics 2015; 47: 1168–1178.
25.
Hwang RF, Moore T, Arumugam T, Ramachandran V, Amos KD, Rivera A, Ji B, Evans DB, Logsdon CD: Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 2008; 68: 918–926.
26.
Banerjee S, Modi S, McGinn O, Zhao X, Dudeja V, Ramakrishnan S, Saluja AK: Impaired synthesis of stromal components in response to minnelide improves vascular function, drug delivery, and survival in pancreatic cancer. Clin Cancer Res 2016; 22: 415–425.
27.
Egeblad M, Ewald AJ, Askautrud HA, Truitt ML, Welm BE, Bainbridge E, Peeters G, Krummel MF, Werb Z: Visualizing stromal cell dynamics in different tumor microenvironments by spinning disk confocal microscopy. Dis Model Mech 2008; 1: 155–167;discussion 165.
28.
Fan M, He T, Zhang P, Zhang J, Li L: Heterogeneity of diffusion-weighted imaging in tumours and the surrounding stroma for prediction of Ki-67 proliferation status in breast cancer. Sci Rep 2017; 7: 2875.
29.
Whiteside TL: The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008; 27: 5904–5912.
30.
Cobrinik D: Retinoblastoma Progression. EBioMedicine 2015; 2: 623–624.
31.
Chen X, Wang J, Cao Z, Hosaka K, Jensen L, Yang H, Sun Y, Zhuang R, Liu Y, Cao Y: Invasiveness and metastasis of retinoblastoma in an orthotopic zebrafish tumor model. Sci Rep 2015; 5: 10351.
32.
Xu XL, Lee TC, Offor N, Cheng C, Liu A, Fang Y, Jhanwar SC, Abramson DH, Cobrinik D: Tumor-associated retinal astrocytes promote retinoblastoma cell proliferation through production of IGFBP-5. Am J Pathol 2010; 177: 424–435.
33.
Pina Y, Boutrid H, Murray TG, Jager MJ, Cebulla CM, Schefler A, Ly LV, Alegret A, Celdran M, Feuer W, Jockovich ME: Impact of tumor-associated macrophages in LH(BETA)T(AG) mice on retinal tumor progression: relation to macrophage subtype. Invest Ophthalmol Vis Sci 2010; 51: 2671–2677.
34.
Murray TG, Cebulla CM, Alegret A, Pina Y, Boutrid H, Jockovich ME: Targeting the tumor microenvironment as a therapeutic strategy for retinoblastoma. Invest Ophthalmol Vis Sci 2007; 48: 1585–1585.
35.
Bond WS, Akinfenwa PY, Perlaky L, Hurwitz MY, Hurwitz RL, Chevez-Barrios P: Tumorspheres but not adherent cells derived from retinoblastoma tumors are of malignant origin. PLoS One 2013; 8:e63519.
36.
Braekeveldt N, Wigerup C, Tadeo I, Beckman S, Sanden C, Jonsson J, Erjefalt JS, Berbegall AP, Borjesson A, Backman T, Ora I, Navarro S, Noguera R, Gisselsson D, Pahlman S, Bexell D: Neuroblastoma patient-derived orthotopic xenografts reflect the microenvironmental hallmarks of aggressive patient tumours. Cancer Lett 2016; 375: 384–389.
37.
Batista A, Riedemann L, Vardam T, Jain RK: Targeting the tumor microenvironment to enhance pediatric brain cancer treatment. Cancer J 2015; 21: 307–313.
38.
Houston SK, Pina Y, Clarke J, Koru-Sengul T, Scott WK, Nathanson L, Schefler AC, Murray TG: Regional and temporal differences in gene expression of LH(BETA)T(AG) retinoblastoma tumors. Invest Ophthalmol Vis Sci 2011; 52: 5359–5368.
39.
Joyce JA, Pollard JW: Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9: 239–252.
40.
Maishi N, Hida K: Tumor endothelial cells accelerate tumor metastasis. Cancer Sci 2017; 108: 1921–1926.
41.
Kalluri R: The biology and function of fibroblasts in cancer. Nat Rev Cancer 2016; 16: 582–598.
42.
Kalluri R, Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer 2006; 6: 392–401.
43.
Kidd ME, Shumaker DK, Ridge KM: The role of vimentin intermediate filaments in the progression of lung cancer. Am J Respir Cell Mol Biol 2014; 50: 1–6.
44.
Chang Y, Li H, Guo Z: Mesenchymal stem cell-like properties in fibroblasts. Cell Physiol Biochem 2014; 34: 703–714.
45.
Li M, Li M, Yin T, Shi H, Wen Y, Zhang B, Chen M, Xu G, Ren K, Wei Y: Targeting of cancer-associated fibroblasts enhances the efficacy of cancer chemotherapy by regulating the tumor microenvironment. Mol Med Rep 2016; 13: 2476–2484.
46.
Qian BZ, Pollard JW: Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141: 39–51.
47.
Allavena P, Mantovani A: Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol 2012; 167: 195–205.
48.
Bingle L, Brown NJ, Lewis CE: The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002; 196: 254–265.
49.
Houston SK, Lampidis TJ, Murray TG: Models and discovery strategies for new therapies of retinoblastoma. Expert Opin Drug Discov 2013; 8: 383–394.
50.
Lee HS, Park SW: Systemic chemotherapy in advanced pancreatic cancer. Gut Liver 2016; 10: 340–347.
51.
Shields CL, Bianciotto CG, Jabbour P, Ramasubramanian A, Lally SE, Griffin GC, Rosenwasser R, Shields JA: Intra-arterial chemotherapy for retinoblastoma: report No. 1, control of retinal tumors, subretinal seeds, and vitreous seeds. Arch Ophthalmol 2011; 129: 1399–1406.
52.
Ghassemi F, Shields CL: Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma. Arch Ophthalmol 2012; 130: 1268–1271.
53.
Munier FL, Gaillard MC, Balmer A, Soliman S, Podilsky G, Moulin AP, Beck-Popovic M: Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. Br J Ophthalmol 2012; 96: 1078–1083.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.